6 dated pricing items. Most recent: We re-checked fifteen compounded prices at source. Fourteen were wrong (2026-08-05).
Pricing is the category that changes fastest and is reported worst. Manufacturer tiers have moved twice in eighteen months, and published compounded figures are wrong more often than they are right.
Why pricing developments matter here
A price is only a fact when it carries a date and a dose. Most coverage supplies neither, which is how a promotional first month becomes a headline annual rate and how a medication-only figure gets compared against an all-in one.
Every item here states the basis: all-in monthly cost, medication plus any recurring fee, at a named dose. Where a figure has been superseded we say what it was and what replaced it, because the correction is usually more useful than the original.
All pricing items
We re-checked fifteen compounded prices at source. Fourteen were wrong
Every correction moved the price upward, which means published 'cheapest' figures across this…
Membership stacking spreads: the advertised price is increasingly not the price
Several programs now split the charge into medication plus a mandatory platform fee, which most…
First-month promotional rates are being published as ongoing prices
A recurring error across round-ups, and the likely origin of several of the wrong figures we…
Mounjaro joins LillyDirect self-pay at 50–60% below list
The diabetes-labelled tirzepatide gets a cash channel, which changes the calculation for anyone…
Zepbound KwikPen reaches self-pay pricing and national pharmacy pickup
The multi-dose pen joins the vial at $299–$449, and Lilly extends self-pay pickup beyond its…
Lilly cuts Zepbound self-pay vial pricing to $299–$449
The starter dose drops from $349 to $299 and the 5 mg vial from $499 to $399, with everything…
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.